Summary of COVID-19 pegipanermin studies

1. Tesi et al., A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)

79 patient pegipanermin late treatment RCT: 290% higher mortality (p=0.36), 241% higher ICU admission (p=0.15), 62% higher progression (p=0.4), and 38% longer hospitalization (p=0.16).
RCT 79 hospitalized COVID-19 patients showing no significant differences with pegipanermin (INB03) treatment.
Nov 2021, NCT04370236, https://clinicaltrials.gov/study/NCT04370236, https://c19p.org/tesi